Tesamorelin: what the evidence actually shows
Tesamorelin is a synthetic growth hormone-releasing factor analogue approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy.
Also known as Egrifta, TH9507.
Evidence and regulatory status
Approved for human use, with published phase 3 data.
Approved by the FDA as Egrifta for HIV-associated lipodystrophy. Not approved for any other indication.
Half-life
A half-life figure for Tesamorelin has not been verified against a primary source for this page, so none is stated. The sources below are where a figure would come from.
What published trials used
- The phase 3 programme administered 2mg once daily by subcutaneous injection over 26 weeks.
Reported for reference only. What a trial administered under supervision is not a recommendation, and Gireta does not make one.
How much research exists
- PubMed records
- 121
- Tagged human
- 100
- Clinical trials
- 28
A PubMed search for Tesamorelin returns 121 records, of which 100 are tagged as human research and 28 are typed as a clinical trial.
Counted on . Counts drift, so the exact query is linked rather than described, and you can re-run it.
Common questions
- What is tesamorelin approved for?
- It is approved for one indication only: excess visceral abdominal fat in people with HIV-associated lipodystrophy. It is not approved for general body composition, anti-ageing or athletic use.
- How does tesamorelin differ from other GH peptides?
- Tesamorelin is one of the few growth hormone secretagogues with an FDA approval and published phase 3 data behind it. Most compounds marketed alongside it, including several on this site, have neither.
- What is the half-life of tesamorelin?
- A half-life figure has not been verified against a primary source for this page, so none is stated. The prescribing information linked below is where one would come from.
Sources
- Egrifta label · DailyMed, US National Library of Medicine, 2025
- Tesamorelin phase 3 · Journal of Acquired Immune Deficiency Syndromes, via PubMed, 2010
Related compounds
Growth hormone secretagogues
Prompt the pituitary to release growth hormone rather than supplying growth hormone directly.
- Ibutamoren Ibutamoren is an orally active ghrelin receptor agonist that raises growth hormone and IGF-1 levels.
- CJC-1295 CJC-1295 is a long-acting analogue of growth hormone-releasing hormone, modified to bind albumin and extend its duration of action.
- Ipamorelin Ipamorelin is a selective growth hormone secretagogue that acts at the ghrelin receptor.
Planning a schedule?
Gireta turns a compound and a cadence into a twelve-week timeline with the reconstitution maths worked out and a monthly cost.
Plan a Tesamorelin scheduleLast reviewed .